
Barry A. Borlaug MD
Associate Professor of Medicine; Director, Circulatory Failure Research, Mayo Clinic, Rochester, MinnesotaDr. Borlaug is a board certified cardiologist, specializing in heart failure and invasive hemodynamic assessment, where he cares for heart failure patients on a regular basis in both the clinics and hospital. He has conducted and collaborated on a number of studies examining the mechanisms of exercise tolerance using both invasive and noninvasive methods in patients with heart failure and is keenly interested in the pathophysiologic underpinnings for exercise tolerance and fatigue in heart failure.
Recent Contributions to PracticeUpdate:
- Effect of Empagliflozin on Blood Volume Redistribution in Patients With Chronic HFrEF
- Prevalence and Prognostic Significance of Microvascular Dysfunction in HFpEF
- β-Blocker Withdrawal May Improve Functional Capacity in Heart Failure and Preserved Ejection Fraction
- Effect of Empagliflozin on Worsening Heart Failure Events in Patients With HFpEF
- Exercise-Stress Real-Time CMR Imaging for Noninvasive Characterization of HFpEF
- Application of Diagnostic Algorithms for HFpEF to the Community
- Gender-Related Differences in HFpEF
- The Hemodynamic Basis of Lung Congestion During Exercise in Patients With HFpEF
- HFpEF Infrequently Evolves Toward a Reduced Phenotype in Long-Term Survivors
- Impact of Baseline Hemodynamics on the Effects of a Transcatheter Interatrial Shunt Device in HFpEF